Gemcitabine and Cisplatin (Gem-Cis) With Erlotinib (Tarceva) in Hepatocellular Carcinoma (HCC) and Biliary Tree Cancer (BTC) (Intra- and Extra-hepatic Cholangiocarcinoma, Bile Duct Cancer, Adenocarcinoma of the Ampulla of Vater and Gallbladder Carcinoma)

Trial Profile

Gemcitabine and Cisplatin (Gem-Cis) With Erlotinib (Tarceva) in Hepatocellular Carcinoma (HCC) and Biliary Tree Cancer (BTC) (Intra- and Extra-hepatic Cholangiocarcinoma, Bile Duct Cancer, Adenocarcinoma of the Ampulla of Vater and Gallbladder Carcinoma)

Discontinued
Phase of Trial: Phase II

Latest Information Update: 18 Apr 2016

At a glance

  • Drugs Erlotinib (Primary) ; Gemcitabine (Primary) ; Cisplatin
  • Indications Liver cancer
  • Focus Therapeutic Use
  • Acronyms Gem-ox
  • Most Recent Events

    • 13 Apr 2016 Planned End Date changed from 1 Dec 2015 to 1 Sep 2016 as reported by ClinicalTrials.gov.
    • 13 Jul 2015 Status changed from active,no longer recruiting to discontinued as reported by ClinicalTrials.gov record.
    • 05 Mar 2013 Planned number of patients changed from 41 to 82 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top